SCHEMBL6174015

SCHEMBL6174015

CCc1nc(-c2cc3c(cc2OC)CCC3)c(CC)nc1NC1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 8/20 0.43
CCR4 P51679 1/20 0.39
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 5/20 0.38
TSHR P16473 4/20 0.38
MAPK1 P28482 4/20 0.38
HSD17B10 Q99714 4/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
USP2 O75604 2/20 0.37
HPGD P15428 2/20 0.37
POLB P06746 2/20 0.37
HTT P42858 1/20 0.37
ALOX15 P16050 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EHMT2 Q96KQ7 2/20 0.37
EHMT1 Q9H9B1 1/20 0.37
NSD2 O96028 1/20 0.36
PDGFRB P09619 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168008 0.98 CRHR1 (0.43) CRHR1CCR4KDM4EALDH1A1TSHR
SCHEMBL6168955 0.83 CRHR1 (0.55) CRHR1
SCHEMBL6167691 0.81 CRHR1 (0.65) CRHR1
SCHEMBL6165487 0.81 CRHR1 (0.55) CRHR1
SCHEMBL6345711 0.80 CRHR1 (0.53) CRHR1
SCHEMBL6351576 0.80 CRHR1 (0.53) CRHR1
SCHEMBL6172207 0.79 CRHR1 (0.56) CRHR1
SCHEMBL6174182 0.79 CRHR1 (0.42) CRHR1ALDH1A1
SCHEMBL6166200 0.79 CRHR1 (0.65) CRHR1
SCHEMBL6175736 0.78 CRHR1 (0.37) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6964965-B2 Substituted pyrazine derivatives PHARMACIA & UPJOHN (US) 2005-11-15 US claimed
EP-1499599-A1 SUBSTITUTED PYRAZINE DERIVATIVES Pharmacia & Upjohn Company LLC (US) 2005-01-26 EP claimed
US-20040053941-A1 Substituted pyrazine derivatives PHARMACIA & UPJOHN COMPANY 2004-03-18 US claimed
WO-2003091225-A1 SUBSTITUTED PYRAZINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-11-06 WO claimed
US-6964965-B2 Substituted pyrazine derivatives PHARMACIA & UPJOHN (US) 2005-11-15 US disclosed
EP-1499599-A1 SUBSTITUTED PYRAZINE DERIVATIVES Pharmacia & Upjohn Company LLC (US) 2005-01-26 EP disclosed
US-20040053941-A1 Substituted pyrazine derivatives PHARMACIA & UPJOHN COMPANY 2004-03-18 US disclosed
WO-2003091225-A1 SUBSTITUTED PYRAZINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053941-A1 Substituted pyrazine derivatives CRHR1, CRHR2, CRH CRHR1 1/4885CCR4 625/4885KDM4E 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.